title: What is the role of concentrated insulin in diabetes management?
abstract: Two concentrated analog insulins, long-acting insulin glargine U-300 (Toujeo) and rapid-acting insulin lispro (Humalog U-200), were recently approved by the FDA. Providers must be aware of clinical differences in these new product formulations compared with their nonconcentrated formulations, so that they can select appropriate patients for these products and minimize drug errors.
authors.affiliation: Cortney M. Mospan is an assistant professor of pharmacy practice at East Tennessee State University's Bill Gatton College of Pharmacy in Johnson City, Tenn. She also serves as a clinical pharmacist with Mooney's Discount Pharmacy in Johnson City. The author has disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Cortney M
authors.initials: CM
authors.lastname: Mospan
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D049528:Insulin, Long-Acting; D061385:Insulins
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D061385:Insulins